References
1. Mackenzie IS, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet : 9 Nov 2020. Available from: URL: https://doi.org/10.1016/S0140-6736(20)32234-0
2. Bardin T, et al. FAST: new look at the febuxostat safety profile. Lancet : 9 Nov 2020. Available from: URL: https://doi.org/10.1016/S0140-6736(20)32343-6
Rights and permissions
About this article
Cite this article
No increased cardiovascular risk with febuxostat versus allopurinol. Reactions Weekly 1830, 10 (2020). https://doi.org/10.1007/s40278-020-85960-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-020-85960-8